Back to the articles list | Back to browse issues page

XML Print

Predicting sickle cell disease severity with hematological parameters, Hb F level, F cell count, Percentage of sickled cells after in vitro induction of sickling and biochemical parameters.
Viren Vaghasiya1 , Divya Bambhaniya2 , Bhoomika Rupavatiya2 , Jitendra Nasit2
1- Medical College Baroda, The M. S. University of Baroda , Viren.vaghasiya-path@msubaroda.ac.in
2- Medical College Baroda, The M. S. University of Baroda
Abstract:   (22 Views)
Background: Sickle cell disease, a hemoglobinopathy due to a point mutation, has a heterogeneous clinical course. HbF level within erythrocytes is believed to be the most important parameter for the severity of disease.
Purpose: To determine whether HbF level, F cell count, and sickle cell percentage after in vitro induction of sickling can predict the severity of the disease.
Methods: All required data was obtained from clinical history, biochemistry, and pathology lab investigations. Statistical analyses were done by using the correlation coefficient and chi-square test to find a significant difference between two variables. Statistical analysis was done using MedCalc software.
Results: Most of the patients are in the mild severity score category; there is a lack of severe disease phenotypes. The number of painful episodes, hospitalizations, and cumulative disease severity scores were associated with high levels of LDH and indirect bilirubin. However, none of the clinical disease severity parameters or the overall cumulative disease severity score were associated with HbF level, F cell count, or the percentage of sickled cells after in vitro induction of sickling. However, a high percentage of F cells was associated with high MCV, MCH, and MCHC and low RDW, LDH, and indirect bilirubin.
Conclusion: This sickle cell disease severity is related to susceptibility of RBCs to hemolysis as indicated by s. LDH and indirect bilirubin levels. However extent of hemolysis may be dependent on multiple factors rather than F cell count or Hb F level only.
Keywords: Sickle cell disease, F cell count, HbF, LDH, Sickle cell percentage
Full-Text [PDF 726 kb]   (11 Downloads)    
Research Article: Research Article | Subject: Laboratory hematology
Received: 2024/02/17 | Accepted: 2024/05/20
References
1. Ashwin PP, Madhuben RN, Nilam MS, Narmadeshwar PS, Prakash HP. Prevalence of common hemoglobinopathies in Gujarat: an analysis of a large population screening program. Natl J Community Med. 2012; 3:112-7. [View at Publisher] [Google Scholar]
2. Jain D, Mohanty D. Clinical manifestations of sickle cell disease in India: misconceptions and reality. Curr Opin Hematol. 2018;25(3):171-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014;123(4):481-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Estepp JH, Smeltzer MP, Kang G, Li C, Wang WC, Abrams C, et al. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Am J Hematol. 2017;92(12):1333-9 [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Hebert N, Rakotoson MG, Bodivit G, Audureau E, Bencheikh L, Kiger L, et al. Fetal hemoglobin quantification per red blood cell allows to determine protective thresholds in sickle cell disease. Am J Hematol. 2020;95(11):1235-45. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Adegoke, Kuti SA, Bankole P. Evaluation of clinical severity of sickle cell anemia in Nigerian children. J App Hematol. 2013;4(2):58-64. [View at Publisher] [Google Scholar]
7. Oyenike MA, Akpan HB, Otulana OJ, Adefule AK, Adedokun KA, Oluogun WA, et al. In-vitro anti-sickling and membrane stability potentials of Mishenland polyherbal extract on sickle red blood cells. Egypt J Haematol. 2019;44(1):65-71. [View at Publisher] [DOI] [Google Scholar]
8. Okocha E, Onwubuya E, Osuji C, Ahaneku G, Okonkwo U, Ibeh N, et al. Disease severity scores and haemogram parameters in Nigerian sickle cell disease patients. J Blood Disord Transfus. 2015;6(6):1-5. [View at Publisher] [DOI] [Google Scholar]
9. Powars DR, Schroeder WA, Weiss JN, Chan LS, Azen SP. Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia. J Clin Invest. 1980;65(3):732-40 [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Ozsoylu S, Altinöz N. Sickle-cell anaemia in Turkey. Evaluation of 97 cases (with parents' findings). Scand J Haematol. 1977;19(1):85-92. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Ali SA. Milder variant of sickle‐cell disease in Arabs in Kuwait associated with unusually high level of foetal haemoglobin. Br J Haematol. 1970;19(5):613-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Haghshenass M, Ismail-Beigi F, Clegg JB, Weatherall DJ. Mild sickle-cell anaemia in Iran associated with high levels of fetal haemoglobin. J Med Geneti. 1977;14(3):168-71. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Gelpi AP. Sickle cell disease in Saudi Arabs. Acta Haematol. 1970;43(2):89-99. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Perrine RP, Brown MJ, Clegg JB, Weatherall DJ, May A. Benign sickle-cell anaemia. Lancet. 1972;2(7788):1163-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs: a study of 270 subjects. Ann Intern Med. 1978;88(1):1-6. [DOI] [PMID] [Google Scholar]
16. Alabid T, Kordofani AA, Atalla B, Babekir A, Elamin BK. Evaluation of clinical severity of sickle cell anemia in Sudanese patients. Am J Res Commun. 2016;4:63-75. [View at Publisher] [Google Scholar]
17. Adegoke, Kuti SA, Bankole P. Evaluation of clinical severity of sickle cell anemia in Nigerian children. J App Hematol. 2013;4(2):58-64. [View at Publisher] [Google Scholar]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.